Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Seyoung | - |
dc.contributor.author | Choi, Dong Wook | - |
dc.contributor.author | Kim, Hong Nam | - |
dc.contributor.author | Park, Chun Gwon | - |
dc.contributor.author | Lee, Wonhwa | - |
dc.contributor.author | Park, Hee Ho | - |
dc.date.accessioned | 2024-01-19T17:04:11Z | - |
dc.date.available | 2024-01-19T17:04:11Z | - |
dc.date.created | 2021-09-05 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/118441 | - |
dc.description.abstract | Nanoparticles have been extensively used as carriers for the delivery of chemicals and biomolecular drugs, such as anticancer drugs and therapeutic proteins. Natural biomolecules, such as proteins, are an attractive alternative to synthetic polymers commonly used in nanoparticle formulation because of their safety. In general, protein nanoparticles offer many advantages, such as biocompatibility and biodegradability. Moreover, the preparation of protein nanoparticles and the corresponding encapsulation process involved mild conditions without the use of toxic chemicals or organic solvents. Protein nanoparticles can be generated using proteins, such as fibroins, albumin, gelatin, gliadine, legumin, 30Kc19, lipoprotein, and ferritin proteins, and are prepared through emulsion, electrospray, and desolvation methods. This review introduces the proteins used and methods used in generating protein nanoparticles and compares the corresponding advantages and disadvantages of each. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.subject | SILK FIBROIN NANOPARTICLES | - |
dc.subject | HUMAN SERUM-ALBUMIN | - |
dc.subject | HIGH-DENSITY-LIPOPROTEIN | - |
dc.subject | CONTROLLED-RELEASE | - |
dc.subject | GLIADIN NANOPARTICLES | - |
dc.subject | PHYSICOCHEMICAL PROPERTIES | - |
dc.subject | TARGETED DELIVERY | - |
dc.subject | HSA-NANOPARTICLES | - |
dc.subject | GENE DELIVERY | - |
dc.subject | CANCER-CELLS | - |
dc.title | Protein-Based Nanoparticles as Drug Delivery Systems | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/pharmaceutics12070604 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.12, no.7 | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 7 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000557152600001 | - |
dc.identifier.scopusid | 2-s2.0-85087164173 | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | SILK FIBROIN NANOPARTICLES | - |
dc.subject.keywordPlus | HUMAN SERUM-ALBUMIN | - |
dc.subject.keywordPlus | HIGH-DENSITY-LIPOPROTEIN | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE | - |
dc.subject.keywordPlus | GLIADIN NANOPARTICLES | - |
dc.subject.keywordPlus | PHYSICOCHEMICAL PROPERTIES | - |
dc.subject.keywordPlus | TARGETED DELIVERY | - |
dc.subject.keywordPlus | HSA-NANOPARTICLES | - |
dc.subject.keywordPlus | GENE DELIVERY | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordAuthor | protein nanoparticle | - |
dc.subject.keywordAuthor | drug delivery | - |
dc.subject.keywordAuthor | biocompatible | - |
dc.subject.keywordAuthor | biodegradable | - |
dc.subject.keywordAuthor | controlled release | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.